29A.F Amphastar P

Healthcare Pharmaceuticals Frankfurt Exchange
25.51 EUR
Close of Nov 11, 2026
13.90 26.00
Market cap
EUR 1.09B
P/E
13.8x
P/B
1.51x
ROE
12.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 29A.F undervalued?

Graham number
Price25.51
Graham value26.54
Discount3.9%

29A.F trades 3.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amphastar P fundamental analysis

No fundamental analysis for Amphastar P yet.

Amphastar P stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amphastar P

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxap…

Full company profile